<DOC>
	<DOCNO>NCT02500290</DOCNO>
	<brief_summary>This study aim describe antiplatelet therapy ACS Andalusia make assessment efficacy safety hospital use Prasugrel / ticagrelor vs. Clopidogrel Prasugrel switch / ticagrelor patient pretreated clopidogrel .</brief_summary>
	<brief_title>Antiplatelet Therapy Acute Coronary Syndrome ( ACS ) . Safety Efficacy Switching Antiplatelet</brief_title>
	<detailed_description>The management acute coronary syndrome change recent year reflect new Clinical Practice Guidelines European Society Cardiology management ACS without ST segment elevation , development increase accessibility angiography percutaneous coronary intervention arrival new antiplatelet ( Prasugrel Ticagrelor ) . The ACS encompass several clinical entity dual antiplatelet therapy remain basis antiplatelet therapy one mainstay treatment . But emergence Prasugrel Ticagrelor change classical management aspirin plus clopidogre</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Patients admit Coronary Care Unit time define initial diagnosis ACS . Myocarditis , Takotsubo syndrome , pulmonary thromboembolism . Secondary MI type 2 , cause increase demand decrease oxygen ( anemia , tachycardia , hypotension , heart failure , etc. ) . 11 Patients 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ACS</keyword>
</DOC>